How Thiostrepton Works: Mechanism of Action in the Published Literature

Short answer: what the literature describes

Thiostrepton is a sulfur rich thiopeptide natural product that medicinal chemists classify as a covalent binder, meaning it carries reactive chemistry capable of forming a lasting bond with certain protein residues. The published pharmacology falls into two broad threads. The first is antibacterial, the context in which the molecule was originally characterised. The second is mammalian cell biology, where researchers have reported engagement of mitochondrial peroxiredoxin 3, subunits of the 19S proteasome regulatory particle, and transcriptional programs organised around the forkhead transcription factor FOXM1. This page summarises what those studies reported and labels each finding by model type.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. No dosing information appears here, and nothing below describes an approved human therapy.

Established mechanism: covalent chemistry on protein targets

Peroxiredoxin 3 and the mitochondrial redox system

The clearest mechanistic framing in recent literature is covalent inhibition of peroxiredoxin 3, a mitochondrial peroxidase that clears hydrogen peroxide. A 2025 report in Science Advances described mechanism based peroxiredoxin 3 inhibitors that exploit a covalent warhead, placing irreversible engagement of the enzyme at the centre of the proposed anticancer mode of action (PMID 41171914). In that framework, loss of peroxiredoxin 3 activity is expected to raise mitochondrial peroxide levels and shift the redox balance of the organelle, a change the study attributed directly to the covalent chemistry rather than to a reversible, concentration dependent block.

A 2026 paper in Nature Communications reported preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer, which makes this the one mechanistic thread in the verified literature that has moved past animal work into an early human setting (PMID 42448681). Early phase testing of a target is not the same as evidence of benefit, and the study framing was mechanism and feasibility rather than outcomes.

The 19S proteasome

Covalent reactivity is not limited to one protein. Researchers reported that thiostrepton interacted covalently with Rpt subunits of the 19S proteasome and with proteasome substrates, a finding that offers a second explanation for the accumulation of ubiquitinated proteins seen in treated cells (PMID 26033448). That study is important for interpreting the wider literature, because proteasome disruption can secondarily change the levels of short lived transcription factors without any direct binding to those factors.

Antibacterial activity and uptake

The antibacterial thread remains part of how the molecule is described. A 2020 report in Antimicrobial Agents and Chemotherapy examined the forging of new antibiotic combinations under iron limiting conditions, a line of work that explores how nutrient restriction changes which antibacterial partners are effective (PMID 31907180). This matters mechanistically because access to the bacterial cytoplasm, not target affinity alone, often decides whether a large natural product behaves as an antibiotic in a given organism.

FOXM1: the most frequently cited downstream node

Across the cancer cell literature, thiostrepton is most often used and described as a FOXM1 inhibitor. FOXM1 is a proliferation associated transcription factor that controls genes involved in cell cycle progression, DNA repair and redox handling. A 2025 study in Translational Oncology reported that thiostrepton suppressed intrahepatic cholangiocarcinoma progression through FOXM1 mediated reprogramming of tumour associated macrophages, meaning the effect described was not purely tumour cell intrinsic but also involved the surrounding immune compartment (PMID 39986191).

An important nuance is whether FOXM1 suppression is a direct or a consequential event. Because the same molecule was reported to bind covalently to Rpt subunits of the 19S proteasome and to proteasome substrates, changes in FOXM1 protein levels can plausibly follow from altered protein turnover rather than from direct inhibition of the transcription factor itself (PMID 26033448). Published work therefore supports FOXM1 pathway suppression as a reproducible observation, while the mechanism upstream of that observation remains a point of active debate.

Downstream signalling reported in cell and animal models

Ferroptosis and the STAT3 to GPX4 axis

Ferroptosis is an iron dependent form of regulated cell death driven by unchecked lipid peroxidation, and glutathione peroxidase 4 is its principal brake. A 2022 study in Cell Death and Disease reported that thiostrepton induced ferroptosis in pancreatic cancer cells through STAT3 and GPX4 signalling, linking transcriptional control of the antioxidant enzyme to the death phenotype observed (PMID 35859150). That mechanism sits comfortably alongside the peroxiredoxin 3 work, since both describe a cell pushed toward peroxide and lipid peroxidation stress (PMID 41171914).

The ferroptosis field also illustrates why resistance matters. A 2026 report in Redox Biology described how ALDH1L2 induced resistance to chemotherapy in small cell lung cancer by inhibiting ferroptosis, which shows that tumour cells carry multiple independent routes to suppress this death pathway (PMID 41764940). Any agent acting through ferroptosis would be expected to encounter the same resistance biology.

Autophagy

Autophagy is a recycling process that can either protect a stressed cell or contribute to its death depending on context. A 2020 article in Autophagy reported autophagy induction by thiostrepton and discussed it in the context of improving anticancer therapy, framing the response as a modifiable part of the compound's cellular profile rather than an incidental artefact (PMID 32330398).

Apoptosis gatekeepers and TGF beta related signalling

A 2024 study in the Journal of Asian Natural Products Research reported that thiostrepton suppressed triple negative breast cancer through downregulation of c-FLIP and SMAD2/3 signalling, implicating both an apoptosis checkpoint protein and a transcriptional arm associated with TGF beta signalling (PMID 38634704). c-FLIP normally restrains death receptor signalling, so its reported loss is consistent with cells becoming easier to kill through that route.

Tumour suppressor regulation

Unbiased screening has added further nodes. A 2025 drug repurposing screen published in Biomolecules identified thiostrepton as a novel regulator of the tumour suppressor DAB2IP (PMID 40867592). Screen derived hits describe an association between compound and pathway, and the study framing was discovery rather than confirmation of a binding event.

Reported targets and model types at a glance

Separating established mechanism from proposed mechanism

Three elements of the mechanism are supported by direct molecular evidence in the verified literature. Covalent engagement of peroxiredoxin 3 was described as the designed basis of a mechanism based inhibitor class (PMID 41171914). Covalent interaction with Rpt subunits of the 19S proteasome and with proteasome substrates was reported directly (PMID 26033448). Antibacterial pharmacology is the historical foundation of the class and remains an active research setting (PMID 31907180).

Other elements are better described as proposed or downstream. FOXM1 suppression, ferroptosis through STAT3 and GPX4, autophagy induction, c-FLIP and SMAD2/3 downregulation, and DAB2IP regulation are all phenotypes reported after exposure in model systems rather than demonstrations of a single binding event (PMID 39986191, PMID 35859150, PMID 40867592). For a covalent, reactive molecule, multiple simultaneous protein interactions are a plausible explanation for this breadth.

Why transcription factor and fibroblast biology appear in adjacent papers

FOXM1 associated biology extends beyond oncology into tissue repair, where the behaviour of fibroblast populations determines whether healing is fibrotic or regenerative. A 2026 report in Cell Reports described how distinct fibroblast assemblies establish scarless regeneration, illustrating why transcriptional control of fibroblast states attracts pharmacological interest (PMID 41447531). That paper describes tissue biology rather than thiostrepton pharmacology, and no bridging human evidence connects the two in the verified literature. A 2022 review surveyed the biological and pharmacological properties of tocotrienols and other naturally occurring compounds, reflecting the broader interest in natural product chemistry from which thiopeptides emerged (PMID 36540866).

Tolerability and human exposure: What Studies Report

The verified literature summarised here is dominated by cell culture and animal work and does not establish a human safety profile for thiostrepton as a systemic agent. The one human facing entry reported preclinical characterization and phase 1 clinical testing of mitochondrial peroxiredoxin 3 targeting in cancer, which is an early stage setting focused on feasibility and pharmacology (PMID 42448681). Mechanistic features that make the molecule interesting, including covalent reactivity toward proteasome subunits and substrates, are also the features that complicate selectivity, and researchers raised that reactivity explicitly (PMID 26033448). Readers should treat all of the above as research description rather than guidance.

Open questions in the mechanism literature

• Whether FOXM1 loss is a direct effect or a consequence of disrupted protein turnover, given the reported covalent proteasome interaction (PMID 26033448).
• How much of the observed cell death depends on redox and ferroptosis pathways versus other routes, since both peroxiredoxin 3 engagement and GPX4 related signalling were reported (PMID 41171914, PMID 35859150).
• Whether autophagy acts as a protective response or a contributor to cell death in a given model (PMID 32330398).
• How resistance mechanisms that block ferroptosis would affect any ferroptosis dependent activity (PMID 41764940).

Related reading

For a broader overview of the compound, its research history and how the evidence base is organised, see the Thiostrepton learn page.

References

• Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling (Cell Death & Disease, 2022)
• Mechanism-based peroxiredoxin 3 inhibitors exploit a covalent warhead for cancer therapy (Science Advances, 2025)
• Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer (Nature Communications, 2026)
• Thiostrepton interacts covalently with Rpt subunits of the 19S proteasome and proteasome substrates (Journal of Cellular and Molecular Medicine, 2015)
• Thiostrepton suppresses intrahepatic cholangiocarcinoma progression via FOXM1-mediated tumor-associated macrophages reprogramming (Translational Oncology, 2025)
• Thiostrepton suppresses triple-negative breast cancer through downregulating c-FLIP/SMAD2/3 signaling pathway (Journal of Asian Natural Products Research, 2024)
• Drug-Repurposing Screen Identifies Thiostrepton as a Novel Regulator of the Tumor Suppressor DAB2IP (Biomolecules, 2025)
• Autophagy induction by thiostrepton for the improvement of anticancer therapy (Autophagy, 2020)
• Forging New Antibiotic Combinations under Iron-Limiting Conditions (Antimicrobial Agents and Chemotherapy, 2020)
• ALDH1L2 induces resistance to chemotherapy in small cell lung cancer by inhibiting ferroptosis (Redox Biology, 2026)
• Distinct fibroblast assemblies establish scarless regeneration (Cell Reports, 2026)
• Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and Naturally Occurring Compounds, Part II (Annals of Clinical Case Reports, 2022)